Literature DB >> 9096447

Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.

D C Tarng1, T P Huang, T W Chen.   

Abstract

Functional iron deficiency occurs when recombinant human erythropoietin (rHuEPO) accelerates erythropoiesis to an extent that the iron availability cannot meet the anticipated demand. Such a phenomenon will reduce the optimal response to rHuEPO. To estimate the iron needs of functional iron deficiency in hemodialysis patients on rHuEPO therapy, we utilized a mathematical method. Forty hemodialysis patients were examined in the study, and all had a baseline serum ferritin (SF) level > 100 microg/l. They were stratified into patients with a transferrin saturation (TfS) value > or = 25% (group I) and those below this value (group II). The treatment protocol consisted of rHuEPO therapy in the two groups for 6 months and iron supplement only in group II. The target hemoglobin level was 10.5 g/dl, and iron metabolism indices were analyzed prior to and following therapy. The results showed (1) in group I (n = 20) hemoglobin rose from 7.5 +/- 0.9 to 10.7 +/- 0.7 g/dl (p < 0.01) and the mean SF level declined from 1,583 +/- 997 to 968 +/- 664 mg (p < 0.01); (2) in group II (n = 20) hemoglobin also increased from 7.8 +/- 0.9 to 10.6 +/- 0.8 g/dl (p < 0.01) following iron supplement, while the SF rose from 183 +/- 70 to 326 +/- 125 mg (p < 0.01); (3) TfS was significantly elevated in group II following iron therapy (18.9 +/- 4.8 vs. 34.5 +/- 9.1%, p < 0.01), and (4) the nomogram showed a sensitivity of 80%, a specificity of 100%, a positive predictive value of 100%, and a negative predictive value of 83% in estimating the iron status before rHuEPO therapy. We conclude that SF levels reflect iron stores and that TfS < 25% is an index of functional iron deficiency. Iron supplementation is not necessary in patients with SF > 100 microg/l and TfS > or = 25%. It seems rational to provide intravenous iron in EPO-resistant patients with functional iron deficiency (SF > 100 microg/l, TfS < 25%). This paper illustrates the importance that accurate assessment of iron needs by a mathematical method would enhance treatment efficacy and avoid iron overload in hemodialysis patients on rHuEPO therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9096447     DOI: 10.1159/000169091

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  4 in total

1.  Erythropoietin prevents dementia in hemodialysis patients: a nationwide population-based study.

Authors:  Peir-Haur Hung; Chih-Ching Yeh; Fung-Chang Sung; Chih-Yen Hsiao; Chih-Hsin Muo; Kuan-Yu Hung; Kuen-Jer Tsai
Journal:  Aging (Albany NY)       Date:  2019-09-05       Impact factor: 5.682

Review 2.  Iron Therapy in Chronic Kidney Disease: Days of Future Past.

Authors:  Kuo-Hua Lee; Yang Ho; Der-Cherng Tarng
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

3.  Association of anemia and iron parameters with mortality among prevalent peritoneal dialysis patients in Taiwan: the AIM-PD study.

Authors:  Ko-Lin Kuo; Jia-Sin Liu; Ming-Huang Lin; Chih-Cheng Hsu; Der-Cherng Tarng
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.379

4.  Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM - HD Study.

Authors:  Ko-Lin Kuo; Szu-Chun Hung; Wei-Cheng Tseng; Ming-Tsun Tsai; Jia-Sin Liu; Ming-Huang Lin; Chih-Cheng Hsu; Der-Cherng Tarng
Journal:  J Am Heart Assoc       Date:  2018-08-07       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.